Loading viewer...
investor_presentation
Format: PDF investor_presentation
Nspr presents its CGuard EPS carotid stent platform leveraging proprietary MicroNet technology for stroke prevention and carotid artery disease treatment. The deck highlights clinical outcomes across 9 trials and 1,850+ patients, market expansion in 30 countries, and anticipated FDA approval in Q1 2025. Company achieved CMS reimbursement approval and closed $113.6M financing to advance commercialization and US regulatory milestones.
investor_presentation
22 Pages
Honeywell International Inc.